| Primary |
| Pneumonia |
18.2% |
| Pulmonary Tuberculosis |
16.6% |
| Bronchitis |
10.9% |
| Tuberculosis |
9.6% |
| Product Used For Unknown Indication |
6.0% |
| Upper Respiratory Tract Infection |
6.0% |
| Hypertension |
4.6% |
| Infection |
4.6% |
| Sinusitis |
3.3% |
| Staphylococcal Infection |
3.3% |
| Respiratory Tract Infection |
2.6% |
| Bronchitis Chronic |
2.0% |
| Keratitis |
2.0% |
| Chronic Obstructive Pulmonary Disease |
1.7% |
| Cough |
1.7% |
| Listeriosis |
1.7% |
| Asthma |
1.3% |
| Immunosuppression |
1.3% |
| Prophylaxis |
1.3% |
| Pyrexia |
1.3% |
|
| Urticaria |
10.5% |
| Infection |
9.2% |
| Anaphylactic Reaction |
7.9% |
| Angioedema |
6.6% |
| Extrasystoles |
6.6% |
| Delirium |
5.3% |
| Ageusia |
3.9% |
| Clostridium Difficile Colitis |
3.9% |
| Clostridium Test Positive |
3.9% |
| Condition Aggravated |
3.9% |
| Convulsion |
3.9% |
| Deep Vein Thrombosis |
3.9% |
| Electrocardiogram Qt Prolonged |
3.9% |
| Hepatic Enzyme Increased |
3.9% |
| Pneumonia |
3.9% |
| Renal Failure Acute |
3.9% |
| Tubulointerstitial Nephritis |
3.9% |
| Visual Acuity Reduced |
3.9% |
| Vomiting |
3.9% |
| Abdominal Pain |
2.6% |
|
| Secondary |
| Product Used For Unknown Indication |
28.5% |
| Tuberculosis |
18.3% |
| Pulmonary Tuberculosis |
9.4% |
| Hiv Infection |
5.4% |
| Mycobacterium Avium Complex Infection |
4.8% |
| Respiratory Tract Infection |
3.5% |
| Osteomyelitis |
3.2% |
| Arthritis Infective |
3.1% |
| Gastrointestinal Infection |
3.1% |
| Genitourinary Tract Infection |
3.1% |
| Skin Infection |
3.1% |
| Antibiotic Prophylaxis |
2.4% |
| Bacterial Infection |
1.8% |
| Bronchopneumonia |
1.8% |
| Oral Candidiasis |
1.8% |
| Pneumonia |
1.8% |
| Antibiotic Therapy |
1.4% |
| Upper Respiratory Tract Infection |
1.2% |
| Bronchitis |
1.2% |
| Abdominal Infection |
1.1% |
|
| Arrhythmia |
10.4% |
| Renal Failure Acute |
7.0% |
| Sudden Death |
7.0% |
| Torsade De Pointes |
7.0% |
| Optic Neuritis |
6.1% |
| Vomiting |
6.1% |
| Drug Ineffective |
5.2% |
| Tubulointerstitial Nephritis |
5.2% |
| Colour Blindness |
4.3% |
| Drug Hypersensitivity |
4.3% |
| Electrocardiogram Qt Prolonged |
4.3% |
| Renal Failure |
4.3% |
| Transaminases Increased |
4.3% |
| Angioedema |
3.5% |
| Death |
3.5% |
| Nausea |
3.5% |
| Ototoxicity |
3.5% |
| Pneumonia Haemophilus |
3.5% |
| Tetany |
3.5% |
| Thrombocytopenia |
3.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
40.2% |
| Adverse Event |
10.0% |
| Drug Use For Unknown Indication |
6.5% |
| Pneumonia |
5.0% |
| Pain |
4.9% |
| Prophylaxis |
4.5% |
| Multiple Myeloma |
3.0% |
| Tuberculosis |
3.0% |
| Hypertension |
2.5% |
| Nausea |
2.5% |
| Chronic Obstructive Pulmonary Disease |
2.3% |
| Infection Prophylaxis |
2.2% |
| Non-small Cell Lung Cancer |
1.9% |
| Hiv Infection |
1.9% |
| Constipation |
1.8% |
| Asthma |
1.7% |
| Anxiety |
1.6% |
| Infection |
1.6% |
| Plasma Cell Myeloma |
1.5% |
| Sedation |
1.3% |
|
| Death |
12.4% |
| Pneumonia |
9.3% |
| Pulmonary Embolism |
9.3% |
| Wheezing |
7.5% |
| Sepsis |
6.8% |
| Renal Failure Acute |
5.6% |
| White Blood Cell Count Increased |
5.6% |
| Thrombocytopenia |
5.0% |
| Pyrexia |
4.3% |
| Vomiting |
4.3% |
| Acute Sinusitis |
3.1% |
| Asthma |
3.1% |
| Cardiac Arrest |
3.1% |
| Cardiac Failure Congestive |
3.1% |
| Drug Interaction |
3.1% |
| Respiratory Failure |
3.1% |
| Unresponsive To Stimuli |
3.1% |
| Weight Decreased |
3.1% |
| Cardiac Failure |
2.5% |
| Drug Ineffective |
2.5% |
|
| Interacting |
| Product Used For Unknown Indication |
47.8% |
| Pulmonary Tuberculosis |
14.5% |
| Prophylaxis |
8.7% |
| Chronic Obstructive Pulmonary Disease |
7.2% |
| Embolism Venous |
4.3% |
| Supplementation Therapy |
4.3% |
| Hiv Infection |
2.9% |
| Hypertension |
2.9% |
| Anticoagulant Therapy |
1.4% |
| Atrial Fibrillation |
1.4% |
| Heart Valve Replacement |
1.4% |
| Pneumonia |
1.4% |
| Thrombosis Prophylaxis |
1.4% |
|
| Anticoagulation Drug Level Above Therapeutic |
30.0% |
| Drug Interaction |
10.0% |
| Dyspnoea |
10.0% |
| International Normalised Ratio Increased |
10.0% |
| Prothrombin Time Prolonged |
10.0% |
| Respiratory Tract Haemorrhage |
10.0% |
| Urogenital Haemorrhage |
10.0% |
| Vomiting |
10.0% |
|
